Skip to main navigation Skip to search Skip to main content

The NHS and the pharmaceutical industry: high risk of harmful interactions

Research output: Contribution to journalArticlepeer-review

Abstract

The pharmaceutical industry has been responsible for many interventions of great benefit to patients. However, great harm to patients and healthcare systems have been created through conflicts of interest, when the behaviours of individual doctors and healthcare systems have been compromised and patient harm has resulted. The interests of the pharmaceutical industry and the NHS cannot be assumed to overlap. This means that medical decision making should be as independent and unbiased as possible. Transparency about conflicts is important, but should be a means to the end it must be part of a system which stops conflicts harming patients and healthcare systems. Given the uncertainty of how the benefits of transparency can be used in practice, it is an imperative that conflicts are avoided, and not just ‘managed’.
Original languageEnglish
Article number100257
Pages (from-to)1-4
Number of pages4
JournalFuture Healthcare Journal
Volume12
Issue number2
Early online date30 Jun 2025
DOIs
Publication statusPublished - Jun 2025

Keywords

  • Conflicts of interest
  • NHS
  • Pharmaceutical industry
  • Bias
  • Evidence based medicine

Fingerprint

Dive into the research topics of 'The NHS and the pharmaceutical industry: high risk of harmful interactions'. Together they form a unique fingerprint.

Cite this